PharmaCyte Biotech Inc. (PMCB) News
Filter PMCB News Items
PMCB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PMCB News From Around the Web
Below are the latest news stories about PHARMACYTE BIOTECH INC that investors may wish to consider to help them evaluate PMCB as an investment opportunity.
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseLAS VEGAS, May 21, 2024--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward |